文献速递白血病造血干细胞移植与细胞治疗

抗自相残杀的CD1a特异性CAR T细胞用于治疗皮质T细胞急性淋巴细胞白血病

Fratricide-resistant CD1a-specific CAR T cells for the treatment of cortical T-cell acute lymphoblastic leukemia.
PubMed 文献 · Blood · 2019-02-22

复发/难治性T细胞急性淋巴细胞白血病(T-ALL)预后差且缺乏有效靶向免疫治疗。CD1a特异性表达于皮质T-ALL(coT-ALL)且在复发时保留。研究开发并临床前验证了CD1a特异性CAR T细胞,体外有强效特异性细胞毒性,异种移植模型中体内有抗白血病活性,且抗自相残杀、长期存续并能响应病毒抗原。

要点

  • CD1a主要表达于发育中的皮质胸腺细胞,CD34+祖细胞和T细胞不表达,限制脱靶毒性风险。
  • CD1a-CARTs在体外对coT-ALL细胞系和患者原代原始细胞有强效特异性细胞毒性。
  • CD1a-CARTs抗自相残杀,在异种移植模型中长期存续并保留抗白血病活性。

核心结论

  • 数据支持抗自相残杀的CD1a-CARTs用于复发/难治性coT-ALL的治疗和安全性。

研究设计与样本

  • 临床前研究:开发CD1a特异性CAR,并在体外及coT-ALL异种移植模型(细胞系和患者来源原代原始细胞)中验证。

主要发现

  • CD1a表达主要局限于发育中的皮质胸腺细胞,CD34+祖细胞和T细胞在个体发育中不表达CD1a。
  • CD1a-CARTs在体外表现出强效且特异性的细胞毒性。
  • CD1a-CARTs在coT-ALL异种移植模型中表现出体内抗白血病活性。
  • CD1a-CARTs抗自相残杀,在体内长期存续,在再攻击实验中保留抗白血病活性,并能响应病毒抗原。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Relapsed/refractory T-cell acute lymphoblastic leukemia (T-ALL) has a dismal outcome, and no effective targeted immunotherapies for T-ALL exist. The extension of chimeric antigen receptor (CAR) T cells (CARTs) to T-ALL remains challenging because the shared expression of target antigens between CARTs and T-ALL blasts leads to CART fratricide. CD1a is exclusively expressed in cortical T-ALL (coT-ALL), a major subset of T-ALL, and retained at relapse. This article reports that the expression of CD1a is mainly restricted to developing cortical thymocytes, and neither CD34+ progenitors nor T cells express CD1a during ontogeny, confining the risk of on-target/off-tumor toxicity. We thus developed and preclinically validated a CD1a-specific CAR with robust and specific cytotoxicity in vitro and antileukemic activity in vivo in xenograft models of coT-ALL, using both cell lines and coT-ALL patient-derived primary blasts. CD1a-CARTs are fratricide resistant, persist long term in vivo (retaining antileukemic activity in re-challenge experiments), and respond to viral antigens. Our data support the therapeutic and safe use of fratricide-resistant CD1a-CARTs for relapsed/refractory coT-ALL.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Sánchez-Martínez D, Baroni ML, Gutierrez-Agüera F, et al. Fratricide-resistant CD1a-specific CAR T cells for the treatment of cortical T-cell acute lymphoblastic leukemia. Blood. 2019. PMID: 30796021. doi:10.1182/blood-2018-10-882944

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。